NO20040407L - Metoder for a mobilisere progenitor/stamceller. - Google Patents

Metoder for a mobilisere progenitor/stamceller.

Info

Publication number
NO20040407L
NO20040407L NO20040407A NO20040407A NO20040407L NO 20040407 L NO20040407 L NO 20040407L NO 20040407 A NO20040407 A NO 20040407A NO 20040407 A NO20040407 A NO 20040407A NO 20040407 L NO20040407 L NO 20040407L
Authority
NO
Norway
Prior art keywords
sub
atoms
nitrogen
formula
fused
Prior art date
Application number
NO20040407A
Other languages
English (en)
Other versions
NO336989B1 (no
Inventor
Geoffrey W Henson
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20040407(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of NO20040407L publication Critical patent/NO20040407L/no
Publication of NO336989B1 publication Critical patent/NO336989B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20040407A 2001-07-31 2004-01-29 Forbindelse for anvendelse i en fremgangsmåte for å behandle en hematopoetisk mangel fra kjemoterapi eller bestrålingsterapi i et individ NO336989B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30919601P 2001-07-31 2001-07-31
US38215502P 2002-05-20 2002-05-20
PCT/US2002/024212 WO2003011277A2 (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells

Publications (2)

Publication Number Publication Date
NO20040407L true NO20040407L (no) 2004-03-19
NO336989B1 NO336989B1 (no) 2015-12-14

Family

ID=26976666

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20040407A NO336989B1 (no) 2001-07-31 2004-01-29 Forbindelse for anvendelse i en fremgangsmåte for å behandle en hematopoetisk mangel fra kjemoterapi eller bestrålingsterapi i et individ
NO20150674A NO344632B1 (no) 2001-07-31 2015-05-27 Forbindelse for anvendelse i metode for å mobilisere og høste progenitor/stamceller
NO2016011C NO2016011I1 (no) 2001-07-31 2016-06-10 plerixafor 1,1'-[1,4-fenylenebis(metylene)]bis[1,4,8,11-tetraazacyclotetradecane]
NO2020003C NO2020003I1 (no) 2001-07-31 2020-03-05 plerixafor (1,1’-[ 1,4-fenylen-bis- (metylen)]- bis1,2,8,11-tetraazacyklotetradekan) eventuelt i form av et farmasøytisk akseptabelt salt eller metallkompleks derav

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO20150674A NO344632B1 (no) 2001-07-31 2015-05-27 Forbindelse for anvendelse i metode for å mobilisere og høste progenitor/stamceller
NO2016011C NO2016011I1 (no) 2001-07-31 2016-06-10 plerixafor 1,1'-[1,4-fenylenebis(metylene)]bis[1,4,8,11-tetraazacyclotetradecane]
NO2020003C NO2020003I1 (no) 2001-07-31 2020-03-05 plerixafor (1,1’-[ 1,4-fenylen-bis- (metylen)]- bis1,2,8,11-tetraazacyklotetradekan) eventuelt i form av et farmasøytisk akseptabelt salt eller metallkompleks derav

Country Status (28)

Country Link
US (9) US6987102B2 (no)
EP (3) EP2371361B1 (no)
JP (2) JP5137288B2 (no)
KR (2) KR20040020075A (no)
CN (2) CN102302493B (no)
AT (1) ATE538785T1 (no)
AU (1) AU2002318927B2 (no)
BE (1) BE2019C544I2 (no)
BR (1) BRPI0211570B8 (no)
CA (1) CA2455559C (no)
CY (4) CY1112633T1 (no)
DK (2) DK1411918T3 (no)
ES (2) ES2380009T3 (no)
FR (2) FR12C0042I1 (no)
HU (1) HUP0402360A2 (no)
IL (2) IL159312A0 (no)
LT (2) LT2371361T (no)
LU (2) LU92033I2 (no)
MX (1) MXPA04000982A (no)
NL (2) NL300537I2 (no)
NO (4) NO336989B1 (no)
NZ (1) NZ530169A (no)
PL (1) PL364673A1 (no)
PT (2) PT1411918E (no)
RU (1) RU2309741C2 (no)
SI (2) SI1411918T1 (no)
WO (1) WO2003011277A2 (no)
ZA (1) ZA200400658B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102302493B (zh) * 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
AU2002357379A1 (en) 2001-12-21 2003-07-15 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
KR101160698B1 (ko) * 2003-06-27 2012-06-28 아사히 가세이 가부시키가이샤 세포 분화 억제제, 이것을 이용하는 세포 배양 방법, 배양 배지 및 배양된 세포주
WO2005002522A2 (en) * 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for treating tissue ischemia
JP2007535479A (ja) 2003-08-13 2007-12-06 チルドレンズ ホスピタル メディカル センター ＧＴＰａｓｅを調節するためのキメラペプチド
US7417026B2 (en) 2003-08-13 2008-08-26 Children's Hospital Medical Center Mobilization of hematopoietic cells
IL158868A0 (en) * 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005103721A1 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4)
CN101094684A (zh) * 2004-08-13 2007-12-26 阿诺麦德股份有限公司 用趋化因子的组合活化祖细胞/干细胞
US7785582B2 (en) * 2004-09-07 2010-08-31 Johnson Lanny L Use of synovium and omentum for tissue engineering
US8182806B2 (en) * 2004-09-07 2012-05-22 Johnson Lanny L Synovial villi for use with tissue engineering
EP1814587A2 (en) 2004-11-05 2007-08-08 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
PT1904084E (pt) 2005-06-13 2013-07-22 Cleveland Clinic Foundation Métodos de proteção contra apoptose mediante uso de lipopéptidos
EP1951046B1 (en) * 2005-08-19 2012-07-18 Genzyme Corporation Methods to enhance chemotherapy
EP1924606A4 (en) * 2005-08-25 2010-01-13 Repair Technologies Inc DEVICES, COMPOSITIONS AND METHODS FOR PROTECTING AND REPAIRING CELLS AND TISSUE
US8518349B2 (en) 2005-09-12 2013-08-27 Lanny Johnson Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US7927630B2 (en) * 2005-09-12 2011-04-19 Johnson Lanny L Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US20070116680A1 (en) * 2005-11-18 2007-05-24 Rensselaer Polytechnic Institute Stem cells within gel microenvironments
US20100035941A1 (en) * 2006-02-24 2010-02-11 Bridger Gary J Methods for increasing blood flow and/or promoting tissue regeneration
WO2007108689A2 (en) * 2006-03-21 2007-09-27 Stichting Skeletal Tissue Engineering Method for induction of differentiation of stem and progenitor cells
CN101500595A (zh) * 2006-08-07 2009-08-05 健赞股份有限公司 组合治疗
US7883698B2 (en) * 2007-01-17 2011-02-08 Maria Michejda Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
US20110245265A1 (en) * 2008-08-29 2011-10-06 Genzyme Corporation Cxcr4 antagonists for kidney injury
US20130039882A1 (en) * 2009-10-28 2013-02-14 Henry Ford Health System Method to mitigate injury from radiation exposure
CN101716167B (zh) * 2009-12-08 2011-12-28 中国人民解放军军事医学科学院野战输血研究所 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
KR20210094672A (ko) 2011-05-16 2021-07-29 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
EP2968563A4 (en) * 2013-03-15 2016-11-30 Leonard B Miller COMBINED TREATMENT TO IMPROVE MOU TISSUE HEALING, HEALING ADIPOSE TISSUE GRAFT, ENDOCHREST BONE SEWAGE AND OSTEOINTEGRATION
US9988973B2 (en) 2015-01-06 2018-06-05 Hamilton Sundstrand Corporation Water injector for aviation cooling system
EP3349797A4 (en) 2015-09-18 2019-06-12 The General Hospital Corporation Dba Massachusetts General Hospital LOCALIZED RELEASE OF ANTIFUGETACTIC AGENT FOR THE TREATMENT OF CANCER
JP6958820B2 (ja) 2015-12-14 2021-11-02 エックス４ ファーマシューティカルズ， インコーポレイテッド がんを処置する方法
CA3008272A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3389720A1 (en) 2015-12-18 2018-10-24 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
JP7055380B2 (ja) 2015-12-22 2022-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 免疫不全疾患を処置するための方法
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017216373A1 (en) * 2016-06-16 2017-12-21 Centre National De La Recherche Scientifique Cxcr4 receptor-binding compounds useful for increasing interferon level
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CN116554168B (zh) 2016-06-21 2025-09-23 X4制药有限公司 Cxcr4抑制剂及其用途
WO2017223229A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
WO2018049120A1 (en) 2016-09-09 2018-03-15 The General Hospital Corporation Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of cancer
US11325951B2 (en) 2016-09-09 2022-05-10 The General Hospital Corporation HSP fusion protein with anti-chemorepellant agent for treatment of cancer
WO2018049124A1 (en) 2016-09-09 2018-03-15 The General Hospital Corporation Hsp fusion protein with anti-chemorepellant agent for treatment of infectious disease
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
IL275077B2 (en) * 2017-12-06 2025-02-01 Magenta Therapeutics Inc Dosing regimens for mobilization of hematopoietic stem and progenitor cells.
JP7517986B2 (ja) * 2017-12-19 2024-07-17 ジーピーシーアール セラピューティクス，インク． Ｇｐｃｒヘテロマー阻害剤及びその用途
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US12059437B2 (en) 2019-10-08 2024-08-13 The Regents Of The University Of California Methods and compositions for hematopoietic stem cell mobilization
EP4117662A4 (en) 2020-03-10 2024-04-03 X4 Pharmaceuticals, Inc. Methods for treating neutropenia
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
EP4408984A1 (en) 2021-10-01 2024-08-07 Janssen Pharmaceutica NV Methods of increasing progenitor cell production
WO2025224720A1 (en) 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors
CN118987175A (zh) * 2024-08-13 2024-11-22 广东壹加再生医学研究院有限公司 普乐沙褔联合粒细胞集落刺激因子在制备治疗脑梗死的药物中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US562476A (en) * 1896-06-23 Combined fence-wire reel and straightener
US4111199A (en) * 1977-03-31 1978-09-05 Isaac Djerassi Method of collecting transfusable granulocytes by gravity leukopheresis
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (de) 1987-08-24 1989-03-16 Schering Ag Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
FR2644453A1 (fr) 1989-03-20 1990-09-21 Centre Nat Rech Scient Procede de preparation de tetramines cycliques monofonctionnalisees
JP3250220B2 (ja) 1989-10-23 2002-01-28 ニコムド サルター インコーポレーテッド マルチサイト金属キレート化剤
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
FR2672051B1 (fr) 1991-01-24 1993-05-21 Guerbet Sa Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
DK0670735T3 (da) 1992-11-13 1997-07-28 Univ Washington Perifisering af hæmotopoietiske stamceller.
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
JPH08127539A (ja) * 1994-10-31 1996-05-21 Ajinomoto Co Inc ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) * 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JPH0952824A (ja) * 1995-06-05 1997-02-25 Nippon Kayaku Co Ltd 末梢血液中の造血幹細胞数を増加するための薬剤
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US5811544A (en) * 1995-08-28 1998-09-22 Johnson Matthey Plc Process for preparing 1,4,8,11-tetraazacyclotetradecane
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
CA2323525C (en) * 1998-03-30 2011-03-01 Gerald P. Murphy Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
AU4696899A (en) * 1998-06-19 2000-01-05 General Hospital Corporation, The Modulating platelet function
CA2244554A1 (en) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition of graft versus host disease
CA2344653A1 (en) 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
JP2002529502A (ja) * 1998-11-17 2002-09-10 スミスクライン・ビーチャム・コーポレイション 血小板減少症の治療法
EP1016413A1 (en) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
MXPA01009674A (es) 1999-03-24 2003-07-21 Anormed Inc Compuestos heterociclicos que se unen a receptores de quimiocina.
AU4692400A (en) * 1999-05-03 2000-11-17 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
CA2389545C (en) * 1999-12-17 2010-08-31 Anormed Inc. Chemokine receptor binding heterocyclic compounds
AU5811001A (en) 2000-05-09 2001-11-20 Univ British Columbia Cxcr4 antagonist treatment of hematopoietic cells
CA2412436C (en) * 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US6734191B2 (en) 2000-09-15 2004-05-11 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
HUP0301094A2 (hu) 2000-09-15 2003-09-29 Anormed Inc. Kemonikinreceptorhoz kötżdż heterociklusos vegyületek, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
AU2001291569B2 (en) 2000-09-15 2007-07-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds
NZ524580A (en) 2000-09-29 2004-10-29 Anormed Inc Process for preparation of N-1 protected N ring nitrogen containing cyclic polyamines and products thereof
EP1361851B1 (en) 2001-01-23 2007-02-21 P & G-Clairol, Inc. Primary intermediates for oxidative coloration of hair
CN102302493B (zh) 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
AU2002357379A1 (en) 2001-12-21 2003-07-15 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
DE102014206089B4 (de) 2014-03-31 2018-01-18 BSH Hausgeräte GmbH Haushaltskältegerät mit einer Spendereinheit mit zwei Verschlusselementen an einem Ausführkanal

Also Published As

Publication number Publication date
CY2019038I2 (el) 2020-05-29
CY2019038I1 (el) 2020-05-29
LU92033I9 (no) 2019-01-03
LT2371361T (lt) 2019-09-10
US20190216773A1 (en) 2019-07-18
KR20090130152A (ko) 2009-12-17
PT2371361T (pt) 2019-09-10
ES2380009T3 (es) 2012-05-07
IL159312A0 (en) 2004-06-01
US20150246019A1 (en) 2015-09-03
US20060193826A1 (en) 2006-08-31
EP1411918A2 (en) 2004-04-28
FR12C0042I1 (fr) 2012-08-10
CY1122199T1 (el) 2020-05-29
US6987102B2 (en) 2006-01-17
KR100996378B1 (ko) 2010-11-25
JP2004538303A (ja) 2004-12-24
WO2003011277A3 (en) 2003-05-22
WO2003011277A2 (en) 2003-02-13
NL300537I2 (no) 2017-02-02
US20170049747A1 (en) 2017-02-23
EP3632425A1 (en) 2020-04-08
MXPA04000982A (es) 2004-04-20
LU92033I2 (fr) 2012-08-27
IL159312A (en) 2015-05-31
CY2012017I1 (el) 2015-08-05
LTC2371361I2 (lt) 2021-09-27
CN102302493B (zh) 2015-08-12
US20130273009A1 (en) 2013-10-17
HK1063005A1 (en) 2004-12-10
NO2020003I1 (no) 2020-03-05
DK1411918T3 (da) 2012-04-23
RU2309741C2 (ru) 2007-11-10
PT1411918E (pt) 2012-03-06
ATE538785T1 (de) 2012-01-15
EP1411918A4 (en) 2007-11-14
SI2371361T1 (sl) 2019-10-30
RU2004105961A (ru) 2005-03-20
LUC00139I1 (no) 2019-11-27
DK2371361T3 (da) 2019-08-19
EP2371361A1 (en) 2011-10-05
HUP0402360A2 (hu) 2005-02-28
FR19C1058I1 (no) 2019-11-22
NO344632B1 (no) 2020-02-17
NZ530169A (en) 2007-04-27
AU2002318927B2 (en) 2007-01-04
NO2016011I1 (no) 2016-06-10
EP1411918B1 (en) 2011-12-28
EP2371361B1 (en) 2019-08-07
ZA200400658B (en) 2005-07-27
JP2008195730A (ja) 2008-08-28
US7897590B2 (en) 2011-03-01
US7935692B2 (en) 2011-05-03
CN1561208A (zh) 2005-01-05
US20030130250A1 (en) 2003-07-10
LUC00139I2 (no) 2021-02-10
CA2455559C (en) 2012-01-10
CA2455559A1 (en) 2003-02-13
CN1561208B (zh) 2010-11-10
ES2742730T3 (es) 2020-02-17
KR20040020075A (ko) 2004-03-06
BR0211570A (pt) 2004-07-13
CY2012017I2 (el) 2015-08-05
BRPI0211570B1 (pt) 2020-01-28
NO20150674A1 (no) 2015-05-27
CY1112633T1 (el) 2015-08-05
SI1411918T1 (sl) 2012-04-30
US20080063624A1 (en) 2008-03-13
LTPA2019018I1 (lt) 2019-12-10
JP5137288B2 (ja) 2013-02-06
NO336989B1 (no) 2015-12-14
NL301031I2 (nl) 2020-07-20
FR19C1058I2 (fr) 2020-10-23
NL301031I1 (nl) 2020-02-05
US20060223180A1 (en) 2006-10-05
US20110129448A1 (en) 2011-06-02
BE2019C544I2 (no) 2021-07-19
BRPI0211570B8 (pt) 2021-05-25
PL364673A1 (en) 2004-12-13
CN102302493A (zh) 2012-01-04

Similar Documents

Publication Publication Date Title
LTPA2019018I1 (lt) Pirmtakų/kamieninių ląstelių suaktyvinimo būdai
AP1497A (en) Methods and compositions to enhance white blood cell count.
HUP0004259A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
AR035218A1 (es) Inhibidores vla-4
ES2164164T3 (es) Derivados de aminotetrazol utiles como inhibidores de oxido nitrico sintasa.
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные
ATE258050T1 (de) Verwendung neurogen-entzuendungshemmender verbindungen und zusammensetzungen
ATE46511T1 (de) Neue 8-alkylthio-2-piperazino-pyrimido(5,4d>pyrimidine, ihre herstellung und diese verbindungen enthaltende arzneimittel.
WO1999023092A3 (en) 3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them
EA200000527A2 (ru) Новые бициклические амино-пиразиноновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA200101050A1 (ru) Замещенные бензолактамные соединения
WO2007106063A3 (en) Methods for increasing blood flow and/or promoting tissue regeneration
EA200001157A2 (ru) Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
FR2823749B1 (fr) Phenyl- et pyridyl-piperidines, procede pour leur preparation et compositions pharmaceutiques les contenant
TH58467A3 (th) ไบไซโคล (2.2.1) เฮพเทนส์ และสารประกอบที่เกี่ยวข้อง

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GENZYME GLOBAL SARL, LU

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GENZYME CORPORATION, US

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: PLERIXAFOR 1,1'-[1,4-FENYLENEBIS(METYLENE)]BIS[1,4,8,11-TETRAAZACYCLOTETRADECANE]; REG. NO/DATE: EU/1/09/537/001 20090810

Spc suppl protection certif: 2016011

Filing date: 20160610

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GENZYME CORPORATION, US

SPCS Change of name or address of the owner of a supplementary protection certificate

Owner name: GENZYME CORPORATION, US

Spc suppl protection certif: 2016011

MK1K Patent expired
SPCW Withdrawal, rejection or dismissal of supplementary protection certificate

Spc suppl protection certif: 2016011